This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Novo Nordisk A/s. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Helle Fabricius Woeldike: Innovator in Diabetes Treatment
Introduction
Helle Fabricius Woeldike is a notable inventor based in Lynge, Denmark. He has made significant contributions to the field of medical science, particularly in the treatment of metabolic disorders.
Latest Patents
Helle holds a patent for N-terminal modified FGF21 compounds. These analogs of FGF21, which carry a modifying, substituted ethylene or benzyl group, can be utilized for the treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and Non-Alcoholic Fatty Liver Disease (NAFLD).
Career Highlights
Helle is currently associated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care and other chronic conditions. His work at Novo Nordisk has positioned him at the forefront of innovative solutions for managing metabolic diseases.
Collaborations
Helle has collaborated with talented colleagues, including Tina Moeller Tagmose and Patrick William Garibay, to advance research and development in his field.
Conclusion
Helle Fabricius Woeldike's innovative work in developing compounds for diabetes treatment showcases his commitment to improving healthcare outcomes. His contributions are vital in the ongoing battle against metabolic diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile